News & Updates

First-line durvalumab plus carboplatin/paclitaxel and bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance significantly improves progression-free survival (PFS) in patients with newly diagnosed non-BRCA-mutated advanced ovarian cancer, when compared with carboplatin/paclitaxel and bevacizumab followed by bevacizumab, as shown in the DUO-O study.

Imlunestrant-based regimens provide clinically meaningful improvements in progression-free survival (PFS), as well as overall survival (OS), in endocrine-pretreated patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC), results of the phase III EMBER-3 trial have shown.

The novel oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) orforglipron gains the upper hand over the current leading oral GLP-1 RA, semaglutide, in individuals with type 2 diabetes (T2D) inadequately controlled on metformin in the phase III ACHIEVE-3 study.